Trametinib is another MEK inhibitor shown to induce a paradoxical proliferative response in KRAS-mutant NSCLC cells as monotherapy by increasing mitochondrial oxidative phosphorylation [79]. Here, MAP2K7 is linked to non-small cell lung carcinoma.